Clinical Trial

Information

FP-101

Fervent Pharmaceutical’s upcoming product is FP-101, a non-hormonal/non-herbal/non-antidepressant treatment that has been shown in preliminary studies to be effective in treating vasomotor symptoms such as hot flashes and night sweats.

FP-101 is an oral formulation of a compound that has known mechanisms of action, is already FDA approved for another indication, and has a long history of safe use. The treatment is currently in the final stages of clinical preparation and Fervent plans to recruit patients for a Phase II Clinical Trial later in 2017.

If you’re a peri-menopausal or post-menopausal woman currently suffering from hot flashes, night sweats, insomnia, or other vasomotor symptoms, you may qualify for our upcoming clinical trial.

Use this map to get more information on trial locations, and visit our research partner at the link below to learn more about enrolling in the trial.

Learn More

FP-101

Fervent Pharmaceutical’s upcoming product is FP-101, a non-hormonal/non-herbal/non-antidepressant treatment that has been shown in preliminary studies to be effective in treating vasomotor symptoms such as hot flashes and night sweats.

FP-101 is an oral formulation of a compound that has known mechanisms of action, is already FDA approved for another indication, and has a long history of safe use. The treatment is currently in the final stages of clinical preparation and Fervent plans to recruit patients for a Phase II Clinical Trial later in 2017.

If you’re a peri-menopausal or post-menopausal woman currently suffering from hot flashes, night sweats, insomnia, or other vasomotor symptoms, you may qualify for our upcoming clinical trial.

Use this map to get more information on trial locations, and visit our research partner at the link below to learn more about enrolling in the trial.

Learn More
Contact Us

740 Greenville Blvd. Suite 400–151
Greenville, NC 27858